These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26741947)

  • 1. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
    Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
    J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
    Ndubaku CO; Heffron TP; Staben ST; Baumgardner M; Blaquiere N; Bradley E; Bull R; Do S; Dotson J; Dudley D; Edgar KA; Friedman LS; Goldsmith R; Heald RA; Kolesnikov A; Lee L; Lewis C; Nannini M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Wallin JJ; Wang L; Wei B; Sampath D; Olivero AG
    J Med Chem; 2013 Jun; 56(11):4597-610. PubMed ID: 23662903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
    Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
    Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
    Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
    J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.
    Stec MM; Andrews KL; Bo Y; Caenepeel S; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Whittington DA; Wang L; Wu T; Zalameda LP; Zhang N; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4136-42. PubMed ID: 26298499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
    Liu Y; Xia Q; Fang L
    Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
    Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
    Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
    Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
    Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
    Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
    J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
    Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.